Headway snaps up six Viveris portfolio companies

The Coller Capital spin-out has purchased six minority stakes in biotech and tech companies via its recently closed €150m secondaries fund.

French private equity firm Viveris Management has sold six minority stakes in portfolio companies to Headway Capital Partners for an undisclosed sum.

The tech and biotech company holdings purchased by London-based Headway, which earlier this month closed its second fund on €150 million ($232 million), represent some of Viveris’ oldest portfolio assets and are a full exit for the firm.

The companies – Trophos, Ipsogen, Maxmat, Certeurope, Travelsoft and Pytheas – were held by Viveris’ first Innoveris fund, a Fonds Communs de Placement dans l’Innovation, or new technology fund that typically targets minority stakes in France’s small- to mid-size early stage companies.

The eight-year old Viveris has raised and managed eight such funds, totaling €190 million. The private equity firm currently manages some €400 million in assets.

Viveris will continue to manage some of the investments sold to Headway, while others will be managed by LC Capital, a Paris-based private equity firm. Specific details were not disclosed.

Headway currently manages €200 million in assets and was founded in early 2004 by Laura Shen Lefranc, Christiaan de Lint and Sebastian Junoy, all formerly of Coller Capital.